Tringale, Kathryn R.
Wolden, Suzanne L.
Karajannis, Matthias
Haque, Sofia
Pasquini, Luca
Yildirim, Onur
Rosenblum, Marc
Benhamida, Jamal K.
Cheung, Nai-Kong
Souweidane, Mark
Basu, Ellen M.
Pandit-Taskar, Neeta
Zanzonico, Pat B.
Humm, John L.
Kramer, Kim
Funding for this research was provided by:
National Institutes of Health (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
Article History
Received: 27 November 2022
Accepted: 30 December 2022
First Online: 28 February 2023
Declarations
:
: Both Memorial Sloan Kettering Cancer Center (MSK) and Dr. Cheung have financial interest in Y-mAbs, Abpro-Labs and Eureka Therapeutics. Dr. Cheung also reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc. Dr. Cheung was named as inventor on multiple patents filed by MSK, including naxitamab and omburtamab licensed to Ymabs Therapeutics, and others licensed to Biotec Pharmacon, and Abpro-labs. Dr. Cheung is a SAB member for Eureka Therapeutics. Dr. Modak and Dr. Kramer reports consulting and equity in Ymabs, Therapeutics Inc. Omburtamab was licensed to Y-mAbs Therapeutics in 2015. Dr. Karajannis reports grants from Y-mAbs Therapeutics, Inc. (research support) and personal fees from Bayer AG, AstraZeneca, Inc., QED Therapeutics, Inc., CereXis, Inc., Recursion, Inc., Cardinal Health and Medscape (Medical Advisory Board and/or consultant).